ClinicalTrials.gg
Active, not recruitingNCT05934890Updated Jul 3, 2024

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13

A Phase 3 interventional study of Walvax PCV13-TT and Pfizer PCV13 in Pneumococcal Disease, Invasive, sponsored by Walvax Biotechnology Co., Ltd.. Active, not recruiting at 2 sites in Indonesia. Open to participants aged 6 Weeks to 8 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Walvax Biotechnology Co., Ltd. · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
630
Allocation
Randomized
Ages
6 Weeks to 8 Weeks
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the immunogenicity and safety of a novel 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13-TT) as compared to Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13) when co-administered with local EPI Vaccines at 2, 4, and 12-15 months of age, to healthy infants in Indonesia. This study aims to demonstrate the non-inferiority of the serotype-specific immune responses elicited by the novel PCV13-TT as compared to PCV13 one month after the booster dose.

02

Conditions studied

  • Pneumococcal Disease, Invasive
03

In context

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

This study's enrollment of 630 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.

Browse Pneumococcal Infections studies →

Lead sponsor

Walvax Biotechnology Co., Ltd. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Weeks to 8 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants must meet ALL the following inclusion criteria for enrollment in the study, at the time of the screening:

    1. Healthy infants based on medical history and clinical assessment.
    2. Age of 6-8 weeks at enrolment. Infants will be eligible since the day they reach 6 weeks of age and until 8 weeks of age included.
    3. Body weight at enrollment ≥3.5 kg.
    4. Infant's parent(s) or legal guardian(s) must be able and willing to provide voluntary written/thumb-printed for the infant to participate in the study.
    5. Infant's parent(s) or legal guardian(s) must be able to comprehend and comply with study requirements and procedures and must be willing and able to return or make themselves available for all scheduled follow-up visits.
    6. Infant's parents must have a readily identifiable place of residence in the study area, be available for the duration of trial participation, and have means of telephone contact.

Exclusion criteria

Exclusion Criteria:

  • The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:

    1. Use of any medicinal product prior to randomization or planned use of such a product during the period of study participation.
    2. History of S. pneumoniae infection as confirmed by medical enquiry or as confirmed by laboratory testing if available.
    3. Participant has fever (axillary temperature ≥ 37.5℃) within 24 hours prior to the 1st dose of vaccination; (If the subject does not meet the criteria, the visit may be rescheduled when the criteria are met.)
    4. The infant who are children in care, preterm and low-birth-weight(Preterm infants have a gestational age below 37 weeks at birth and low-birth-weight infants have a birth weight below 2.5 kg).
    5. History of allergic disease or history of a serious reaction to any prior vaccination or known to any component of the 2 study vaccines. This includes all components of the EPI vaccines.
    6. History of anaphylactic shock.
    7. Any abnormal vital sign.
    8. Any moderate or severe acute illness.
    9. History of administration of a non-study vaccine within 30 days prior to administration of study vaccine, other than EPI vaccinations (Note: EPI vaccines other than that stipulated in the study must be given at least 14 days prior to the investigational vaccine.)
    10. Individuals who receive treatment with radiotherapy or therapy, including cytotoxic agents or systemic (if systemic corticosteroids are administered for 14 days at a dose of 20 mg/day of prednisone or equivalent), e.g., for cancer or an disease, or planned receipt throughout the study. Inhaled/nebulized, intra-articular, epidural, or topical (skin or eyes) corticosteroids within indicated dosage are permitted.
    11. Administration of immunoglobulins and/or any blood products or anticipation of such administration during the study period.
    12. History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding (e.g., thalassemia, coagulation factor deficiencies, severe anemia at birth).
    13. History of suspected primary immunodeficiency.
    14. History of meningitis, seizures or any neurological disorder.
    15. A family history of congenital or hereditary immunodeficiency.
    16. The infant is a direct descendant (child or grandchild) of any person employed by the Sponsor, the CRO, the investigator, study site personnel.
    17. Any medical or social condition that in the opinion of the investigator may compromise the well-being of the study participant, interfere with the study objectives, pose a risk to the study participant, or prevent the study participant from completing the study follow-up.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
630 participants (actual)

Study arms

  • Experimental
    Walvax PCV13-TT

    Primary Vaccination: A total of approximately 300 infants 6-8 weeks of age will be enrolled and assigned randomly to receive at 2, 4, and 12-15 months of age 1 dose of PCV13-TT. Standard EPI vaccines will be administered concomitantly. Booster Vaccination: At 12-15 months of age (8 to 11 months after the 2nd dose of the primary series), infants will receive a booster dose of PCV13-TT.

    Biological: Walvax PCV13-TT

  • Active comparator
    Pfizer PCV13

    Primary Vaccination: A total of approximately 300 infants 6-8 weeks of age will be enrolled and assigned randomly to receive at 2, 4, and 12-15 months of age 1 dose of PCV13. Standard EPI vaccines will be administered concomitantly. Booster Vaccination: At 12-15 months of age (8 to 11 months after the 2nd dose of the primary series), infants will receive a booster dose of PCV13.

    Biological: Pfizer PCV13

Interventions

  • BiologicalWalvax PCV13-TT

    PCV13-TT is supplied as 0.5 mL prefill syringe (PFS), with 0.5 mL suspension for intramuscular injection. After shaking, the vaccine is a homogenous, white suspension. Each dose (0.5 mL) of PCV13-TT contains pneumococcal polysaccharide serotypes 1, 3 4, 5, 6A 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F which are conjugated to TT carrier protein individually. The vaccine is formulated in phosphate-buffered saline containing 4.25 mg/dose sodium chloride (NaCl), 44.35 μg/dose sodium dihydrogen phosphate (NaH2PO4), 19.0 μg/dose disodium hydrogen phosphate (Na2HPO4), and contains 0.5 mg/dose of aluminum phosphate as an adjuvant; no preservatives added.

  • BiologicalPfizer PCV13

    PCV13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes. Each 0.5 mL dose of PCV13 is formulated to contain approximately 2.2 μg of each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F polysaccharides, 4.4 μg of 6B polysaccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.

06

What researchers measure

Primary outcomes

  1. Immunogenicity and non-inferiority as measured by serotype-specific IgG

    Percentage of infants with serotype-specific IgG concentrations ≥0.35 μg/mL

    Time frame: 1 month after the booster dose

  2. Immunogenicity and non-inferiority as measured by serotype-specific IgG GMC

    Serotype-specific IgG GMCs

    Time frame: 1 month after the booster dose

Secondary outcomes

  1. Solicited local and systemic adverse events after each dose

    Frequency and severity of solicited local and systemic adverse events (AEs)

    Time frame: within 30 min and 7 days after each dose

  2. Unsolicited adverse events after each dose

    Frequency and severity of unsolicited AEs

    Time frame: within 30 days after each dose

  3. Serious adverse events throughout the study

    Frequency of serious AEs (SAEs)

    Time frame: from dose 1 until 6 months after booster dose

  4. Immune response to primary series as measured by serotype-specific IgG

    Percentage of infants with pneumococcal serotype-specific IgG concentrations ≥0.35 µg/mL

    Time frame: 1 month after the 2nd dose

  5. Immune response to primary series as measured by serotype-specific IgG GMC

    Serotype-specific IgG GMCs

    Time frame: 1 month after the 2nd dose

  6. Functional antibody responses as measured by serotype-specific OPA titer

    Percentage of infants with serotype-specific OPA titer ≥1:8

    Time frame: baseline, 1 month after the 2nd dose, before the booster dose, and 1 month after the booster dose

  7. Functional antibody responses as measured by serotype-specific OPA geometric mean titers (GMTs)

    Serotype-specific OPA geometric mean titers (GMTs)

    Time frame: baseline, 1 month after the 2nd dose, before the booster dose, and 1 month after the booster dose

  8. Immune persistence as measured by serotype-specific IgG

    Percentage of infants with pneumococcal serotype-specific IgG concentrations ≥0.35 µg/mL

    Time frame: 12-15 months of age, before the booster dose

  9. Immune persistence as measured by serotype-specific IgG GMC

    Serotype-specific IgG GMCs

    Time frame: 12-15 months of age, before the booster dose

Other outcomes

  1. Exploratory_Non-interference

    Percentage of infants with anti-diphtheria toxoid IgG concentrations ≥0.1 IU/mL

    Time frame: 1 month after the 2nd dose

  2. Exploratory_Non-interference

    Percentage of infants with anti-tetanus toxoid IgG concentrations ≥0.1 IU/mL

    Time frame: 1 month after the 2nd dose

  3. Exploratory_Non-interference

    Proportion of subjects with 4-fold increase in anti-pertussis IgG concentration

    Time frame: 1 month after the 2nd dose with respect to baseline titers

  4. Exploratory_Non-interference

    Percentage of infants with anti Haemophilus influenzae type b (PRP) IgG concentration ≥0.15 µg/mL

    Time frame: 1 month after the 2nd dose.

  5. Exploratory_Non-interference

    Percentage of infants with anti Hepatitis B surface antigen (hBsAg) IgG oncentrations ≥10 mIU/mL

    Time frame: 1 month after the 2nd dose.

  6. Exploratory_Non-interference

    Percentage of infants with anti poliovirus types 1, 2 and 3 neutralizing antibody titers ≥1:8 measured

    Time frame: 1 month after the 2nd dose.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Mar 2025, 16 months after the start.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 16 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2023
First posted
Jul 7, 2023
StartActual
Nov 23, 2023
Primary completionEst.
Mar 2025
CompletionEst.
Feb 2026
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05934890
Lead sponsor
Walvax Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jul 7, 2023
Start date
Nov 23, 2023
Primary completion
Mar 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
Jul 3, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion